Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

NCT04674969 · View on ClinicalTrials.gov ↗

Study Summary

The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.

Interventions

  • DEVICE Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.

Study Locations (20)

California

  • PIH Health Good Samaritan Hospital — Los Angeles
  • Cedars - Sinai Medical Center — Los Angeles
  • Ronald Reagan UCLA Medical Center — Los Angeles
  • Sutter Medical Center, Sacramento — Sacramento
  • Adventist Health St Helena Hospital — St. Helena

Louisiana

  • CIS Clinical Research Corporation — Houma
  • Ochsner Clinic Foundation — Kenner
  • Cardiovascular Institute of the South — Lafayette

Florida

  • Palm Beach Heart & Vascular, LLC — Boynton Beach
  • Tallahassee Memorial Hospital — Tallahassee

Georgia

  • Emory University Hospital — Atlanta
  • South Georgia Medical Center — Valdosta

Illinois

  • Rush University — Chicago
  • St. John's Hospital/ Prairie Education and Research Cooperative — Springfield

Indiana

  • St. Joseph Hospital/Dupont Hospital — Fort Wayne
  • Ascension St. Vincent's Hospital — Indianapolis

Arkansas

  • St. Bernard's Medical Center — Jonesboro

Connecticut

  • Yale University School of Medicine — New Haven

Trial Details

FieldValue
Enrollment Target 5,000 participants
Start Date 2021-03-29
Est. Completion 2028-01

Sponsor

Boston Scientific Corporation

120 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04674969

The ClinicalTrials.gov registry entry for NCT04674969 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 120 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Peripheral Vascular Diseases appearing as the primary indexed condition, and to 1 intervention — of which Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device. is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04674969 reports 20 study locations spanning 10 distinct geographic areas — top geographies include California, Louisiana, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04674969 about?

NCT04674969 is a clinical study titled "Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature". The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices f...

What is the current status of trial NCT04674969?

This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2021-03-29. Estimated completion is 2028-01.

What conditions does trial NCT04674969 study?

This clinical trial studies the following conditions: Peripheral Vascular Diseases. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04674969?

The interventions under investigation include: Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device. (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04674969?

This trial is sponsored by Boston Scientific Corporation, which has 120 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04674969 being conducted?

This trial has 20 study locations across Arkansas, California, Connecticut, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial